| Literature DB >> 31924237 |
Sigrun Wohlfart1, Ralph Meiller2, Johanna Hammersen3, Jung Park3, Johannes Menzel-Severing4, Volker O Melichar3, Kenneth Huttner5, Ramsey Johnson5, Florence Porte6, Holm Schneider3.
Abstract
BACKGROUND: X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by pathogenic variants of the gene EDA disrupting the prenatal development of ectodermal derivatives. Cardinal symptoms are hypotrichosis, lack of teeth, and hypo- or anhidrosis, but the disease may also evoke other clinical problems. This study aimed at investigating the clinical course of XLHED in early childhood as the basis for an evaluation of the efficacy of potential treatments.Entities:
Keywords: Dry eye; Ectodysplasin A; Heat intolerance; Hypohidrotic ectodermal dysplasia; Natural history; Oligodontia
Mesh:
Substances:
Year: 2020 PMID: 31924237 PMCID: PMC6954509 DOI: 10.1186/s13023-019-1288-x
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
EDA genotype of the study participants and data related to their sweating ability
| Code | Age at enrolment (months) | Changes at the amino acid level | Pilocarpine-induced sweat volume (μL) | Sweat pores/cm2 (plantar) | Body temperature (°C; average of independent measurements) | |
|---|---|---|---|---|---|---|
| Male subjects | ||||||
| M3–001 | 17 | c.608C > T | p.Pro203Leu | 0.0 | 22.2 | 37.15 |
| M3–002 | 35 | c.467_468del | p.Arg156GlnfsX2 | 0.0 | 1.4 | 36.90 |
| M3–003 | 35 | c.467G > A | p.Arg156His | 0.0 | 0.0 | 36.95 |
| M3–005 | 27 | c.1075A > T | p.Lys359X | 0.0 | 0.0 | 37.25 |
| M3–007 | 24 | c.463C > T | p.Arg155Cys | 0.0 | 5.6 | 37.10 |
| M3–008 | 11 | c.1133C > T | p.Thr378Met | 0.0 | 0.0 | 36.90 |
| M3–009 | 33 | c.1141G > C | p.Gly381Arg | 0.0 | 0.0 | 37.15 |
| M3–012 | 22 | c.467G > A | p.Arg156His | 0.0 | 0.0 | 37.15 |
| M3–013 | 27 | c.376_379del | p.Asp126ProfsX10 | 0.0 | 2.8 | 36.85 |
| M3–014 | 33 | c.793G > T | splice-site alteration | 0.0 | 0.0 | 37.20 |
| M3–015 | 17 | c.925-3C > G | splice-site alteration | 0.0 | 0.0 | 36.95 |
| M3–016 | 21 | c.502 + 1G > A | splice-site alteration | 0.0 | 8.3 | 37.35 |
| M3–017 | 28 | c.463C > T | p.Arg155Cys | 0.0 | 13.9 | 37.05 |
| M3–018 | 29 | c.467G > A | p.Arg156His | 0.0 | 0.0 | 37.00 |
| M3–019 | 26 | duplication of exons 3–8 | 0.0 | 41.7 | 36.90 | |
| M3–020 | 31 | c.1072C > T | p.Gln358X | 0.0 | 0.0 | 36.50 |
| M3–022 | 28 | c.911A > G | p.Tyr304Cys | 0.0 | 0.0 | 36.80 |
| M3–023 | 17 | c.648_665del18 | p.Pro216_Gly221del | 0.0 | 0.0 | 36.65 |
| M3–025 | 26 | c.1133C > T | p.Thr378Met | 0.0 | 0.0 | 37.05 |
| Average | 25.63 | / | / | 0.00 | 5.05 | 36.99 |
| SD | 6.73 | 0.00 | 10.67 | 0.21 | ||
| Female subjects | ||||||
| F3–004 | 35 | c.467G > A | p.Arg156His | 23.0 | 625 | 37.20 |
| F3–006 | 25 | c.1112 T > A | p.Ile371Asn | 9.0 | u.a. | 37.05 |
| F3–010 | 35 | c.572_589del | p.Pro191_Pro196del | 16.0 | u.a. | 37.00 |
| F3–011 | 31 | c.659_676del | p.Pro220_Pro225del | 17.0 | 850 | 37.20 |
| F3–021 | 31 | c.1072C > T | p.Gln358X | 22.0 | 825 | 37.05 |
| F3–024 | 21 | c.546_581del36 | p.Asn185_Pro196del | 55.0 | 775 | 37.35 |
| Average | 29.67 | 23.67 | 768.75 | 37.14 | ||
| SD | 5.61 | 16.15 | 100.78 | 0.13 | ||
Abbreviations: SD standard deviation
Fig. 1Plantar sweat duct densities in trizygotic triplets as determined by confocal laser scanning microscopy. Left: plantar area of 2.25 mm2. Right: magnification of a representative section. a female triplet without EDA mutation. b subject F3–004, heterozygous for the EDA variant c.467G > A. c subject M3–003, hemizygous for the indicated EDA variant
History regarding heat intolerance prior to enrolment
| Code | Unexplained fevers | Associated seizures | Hospitalization due to heat intolerance | If yes, diagnosis | Reported heat intolerance | Impact of heat intolerance/reduced sweating on: | |||
|---|---|---|---|---|---|---|---|---|---|
| daily life | outdoor sports | choice of vacation destinations | ability to travel | ||||||
| Male subjects | |||||||||
| M3–001 | Y | N | N | / | Y | N | N | Y | Y |
| M3–002 | Y | N | Y | suspicion of pneumonia | Y | Y | N | Y | Y |
| M3–003 | Y | N | N | / | Y | Y | N | Y | Y |
| M3–005 | Y | N | Y | therapy-resistant hyperpyrexia | Y | Y | Y | Y | Y |
| M3–007 | Y | N | N | / | Y | N | N | Y | Y |
| M3–008 | Y | Y | Y | spasmodic laryngitis | Y | N | N | Y | Y |
| M3–009 | Y | N | N | / | Y | N | N | Y | Y |
| M3–012 | Y | N | Y | suspicion of respiratory tract infection | Y | N | N | Y | Y |
| M3–013 | Y | N | N | / | Y | Y | N | Y | Y |
| M3–014 | Y | N | N | / | Y | N | N | Y | Y |
| M3–015 | Y | N | Y | hyperpyrexia | Y | Y | N | Y | Y |
| M3–016 | N | N | N | / | Y | N | N | Y | Y |
| M3–017 | Y | N | N | / | Y | Y | N | Y | Y |
| M3–018 | Y | N | Y | fever, dehydration | Y | Y | Y | Y | Y |
| M3–019 | Y | N | N | / | Y | N | Y | Y | Y |
| M3–020 | Y | N | N | / | Y | Y | Y | Y | Y |
| M3–022 | Y | N | N | / | Y | N | N | Y | Y |
| M3–023 | Y | N | N | / | Y | N | N | Y | Y |
| M3–025 | Y | N | Y | unexplained fever | Y | Y | Y | Y | Y |
| Female subjects | |||||||||
| F3–004 | N | N | N | / | N | N | N | N | N |
| F3–006 | N | N | N | / | N | N | N | N | N |
| F3–010 | N | N | N | / | N | N | N | N | N |
| F3–011 | N | N | N | / | N | N | N | N | N |
| F3–021 | N | N | N | / | N | N | N | Y | N |
| F3–024 | N | N | N | / | N | N | N | N | N |
Abbreviations: Y yes; N no
Physical exam findings
| Detected abnormality | Number of affected individuals (%) | |
|---|---|---|
| Male subjects | Female subjects | |
| Hypo-, oligo- or anodontia (for more details see Table | 19 (100) | 5 (83) |
| Lack or absence of eyebrows | 19 (100) | 5 (83) |
| Dry skin | 19 (100) | 1 (17) |
| Hypo- or atrichia | 19 (100) | 0 (0) |
| Sparse eyelashes | 17 (89) | 0 (0) |
| Hypoplastic jaws | 16 (84) | 1 (17) |
| Dysplastic or protruding ear(s) | 16 (84) | 0 (0) |
| Frontal bossing | 16 (84) | 0 (0) |
| Eklabium | 12 (63) | 1 (17) |
| Eczematous skin | 10 (53) | 1 (17) |
| Supernumerary nipple and/or nipples of different size | 5 (26) | 0 (0) |
| Initially retarded psychomotor development (later normal status) | 4 (21) | 0 (0) |
| Growth retardation | 2 (11) | 2 (33) |
| Conjunctivitis, inflamed lid margins | 2 (11) | 0 (0) |
Fig. 2Growth charts of subjects with XLHED between 0 and 60 months of age in comparison with standardized percentiles for the normal population depicting a length-for-age (cm), b weight-for-age (kg), and c BMI-for-age (kg/m2) [21]. The filled circles represent a girl from Israel with normal birth weight but obvious growth retardation later on
Fig. 3Number of erupted teeth in male and female subjects with XLHED at the age of 24, 36, 48 and 60 months
Number of deciduous teeth and tooth buds of the permanent dentition per quadrant
| Code | Quadrant 1 | Quadrant 2 | Quadrant 3 | Quadrant 4 | Total number of teeth/tooth buds |
|---|---|---|---|---|---|
| Male subjects | |||||
| M3–001 | 2 + 1 | 2 + 1 | 1 + 0 | 0 + 0 | 5 + 2 |
| M3–002 | 1 + 2 | 0 + 2 | 0 + 0 | 0 + 0 | 1 + 4 |
| M3–003 | 1 + 2 | 1 + 2 | 0 + 2 | 0 + 1 | 2 + 7 |
| M3–005 | 1 + 0 | 1 + 0 | 0 + 0 | 0 + 0 | 2 + 0 |
| M3–007 | 3 + 2 | 3 + 2 | 3 + 1 | 3 + 1 | 12 + 6 |
| M3–008 | 3 + 3 | 3 + 3 | 1 + 1 | 1 + 1 | 8 + 8 |
| M3–009 | 2 + 2 | 2 + 1 | 1 + 1 | 1 + 1 | 6 + 5 |
| M3–012 | 2 + 1 | 2 + 0 | 0 + 0 | 0 + 0 | 4 + 1 |
| M3–013 | 1 + 2 | 1 + 2 | 0 + 1 | 0 + 1 | 2 + 6 |
| M3–014 | 3 + 2 | 3 + 2 | 0 + 1 | 1 + 1 | 7 + 6 |
| M3–015 | 3 + 1 | 1 + 1 | 0 + 0 | 0 + 0 | 4 + 2 |
| M3–016 | 3 + 2 | 3 + 2 | 0 + 1 | 0 + 1 | 6 + 6 |
| M3–017 | 3 + 2 | 3 + 3 | 2 + 0 | 2 + 0 | 10 + 5 |
| M3–018 | 1 + 2 | 1 + 2 | 0 + 0 | 0 + 1 | 2 + 5 |
| M3–019 | 1 + 0 | 1 + 1 | 0 + 0 | 0 + 0 | 2 + 1 |
| M3–020 | 2 + 2 | 2 + 2 | 1 + 1 | 1 + 1 | 6 + 6 |
| M3–022 | 2 + 0 | 2 + 0 | 0 + 0 | 0 + 0 | 4 + 0 |
| M3–023 | 1 + 0 | 1 + 0 | 1 + 1 | 1 + 1 | 4 + 2 |
| M3–025 | 1 + 0 | 1 + 0 | 1 + 0 | 1 + 0 | 4 + 0 |
| Average | 1.90 + 1.37 | 1.74 + 1.37 | 0.58 + 0.53 | 0.58 + 0.53 | 4.79 + 3.79 |
| SD | 0.88 + 0.96 | 0.93 + 1.01 | 0.84 + 0.61 | 0.84 + 0.51 | 2.94 + 2.64 |
| Female subjects | |||||
| F3–004 | 4 + 5 | 4 + 5 | 5 + 6 | 5 + 6 | 18 + 22 |
| F3–006 | 3 + 5 | 1 + 3 | 1 + 2 | 3 + 3 | 8 + 13 |
| F3–010 | 5 + 6 | 5 + 6 | 5 + 7 | 5 + 7 | 20 + 26 |
| F3–011 | 4 + 5 | 3 + 3 | 3 + 5 | 5 + 5 | 15 + 18 |
| F3–021 | 5 + 7 | 5 + 7 | 5 + 7 | 5 + 7 | 20 + 28 |
| F3–024 | 4 + 4 | 4 + 4 | 5 + 7 | 5 + 7 | 18 + 22 |
| Average | 4.17 + 5.33 | 3.67 + 4.67 | 4.00 + 5.67 | 4.67 + 5.83 | 16.5 + 21.5 |
| SD | 0.75 + 1.03 | 1.51 + 1.63 | 1.67 + 1.97 | 0.82 + 1.60 | 4.55 + 5.43 |
Ophthalmic assessments
| Code | Corneal examination | Meibomian gland openingsa | BUT (s) | OSDI score | Schirmer’s test (mm) | |||
|---|---|---|---|---|---|---|---|---|
| Right eye | Left eye | Right eye | Left eye | Right eye | Left eye | |||
| Male subjects | ||||||||
| M3–001 | SPK (on both sides) | 1 | 2 | 3 | 3 | 11.1 | 12 | 10 |
| M3–002 | N | 0 | 0 | 3 | 2 | 0.0 | 5 | 6 |
| M3–003 | SPK (on both sides) | 2 | 3 | 2 | 4 | 8.3 | u.a. | u.a. |
| M3–005 | N | 3 | 1 | 5 | 4 | 5.0 | 11 | 5 |
| M3–007 | N | 0 | 0 | 10 | 12 | 2.5 | u.a. | u.a. |
| M3–008 | SPK (on both sides) | 2 | 3 | 1 | 2 | 13.8 | 20 | u.a. |
| M3–009 | N | 5 | 4 | 4 | 4 | 5.0 | 10 | 4 |
| M3–012 | N | 0 | 0 | u.a. | u.a. | 5.0 | 12 | 17 |
| M3–013 | SPK (on both sides) | 1 | 3 | 5 | 5 | 11.1 | 6 | 11 |
| M3–014 | N | 1 | 1 | 10 | 11 | 5.0 | 7 | 4 |
| M3–015 | u.a. | 0 | 3 | 5 | 6 | 8.3 | u.a. | u.a. |
| M3–016 | SPK (on both sides) | 0 | 0 | 8 | 10 | 5.5 | u.a. | u.a. |
| M3–017 | N | 0 | 2 | 12 | 12 | 2.7 | 14 | > 25 |
| M3–018 | SPK (on both sides) | 1 | 2 | 4 | 4 | 19.4 | u.a. | u.a. |
| M3–019 | N | 6b | 9b | 7 | u.a. | 2.7 | 16 | 10 |
| M3–020 | SPK (on both sides) | 1 | 0 | u.a. | u.a. | 22.2 | u.a. | u.a. |
| M3–022 | N | 1 | 1 | u.a. | u.a. | 5.0 | u.a. | u.a. |
| M3–023 | N | 1 | 0 | u.a. | u.a. | 5.0 | u.a. | u.a. |
| M3–025 | N | 6 | 6 | u.a. | u.a. | 2.7 | > 25 | > 25 |
| Average | / | 1.39 | 1.72 | 5.64 | 6.08 | 7.38 | / | / |
| SD | / | 1.72 | 1.71 | 3.30 | 3.77 | 5.85 | / | / |
| Female subjects | ||||||||
| F3–004 | N | > 20 | > 20 | 14 | 14 | 0.0 | u.a. | u.a. |
| F3–006 | N | 9 | 8 | 14 | 12 | 11.1 | u.a. | u.a. |
| F3–010 | N | 8 | 5 | 8 | 6 | 2.5 | 4 | u.a. |
| F3–011 | N | > 20 | > 20 | 9 | 8 | 2.5 | 10 | 5 |
| F3–021 | N | 6 | 5 | 12 | 10 | 0.0 | > 25 | > 25 |
| F3–024 | N | 5 | 5 | u.a. | u.a. | 0.0 | u.a. | u.a. |
Abbreviations: a, maximum number detected in the lower lid during two independent examinations; N, normal; SPK, superficial punctate keratitis; u.a., unable to assess; b, not fully developed
Fig. 4a Infrared images of the everted lower eyelid highlight some rudimentary Meibomian gland ducts (white dots) in a representative male subject with XLHED. b more than 20 fully developed Meibomian gland ducts, extending from the lower tarsus to the orifices at the lid margin, in an age-matched healthy control
Adverse events (AEs) / serious adverse events (SAEs) during the observation period
| Male subjects | Female subjects | |||||
|---|---|---|---|---|---|---|
| Event | Number of subjects (%) | AEs | Thereof SAEs | Number of subjects (%) | AEs | Thereof SAEs |
| 1. XLHED-related infections | ||||||
| Respiratory | 14 (74) | 25 | 7 | 3 (50) | 5 | 0 |
| Ear | 4 (21) | 15 | 3 | 1 (17) | 6 | 0 |
| Skin | 2 (11) | 5 | 0 | 2 (33) | 4 | 0 |
| Nose | 4 (21) | 4 | 0 | 1 (17) | 1 | 0 |
| Eye | 1 (5) | 1 | 0 | 1 (17) | 1 | 0 |
| Other | 0 (0) | 0 | 0 | 1 (17) | 3 | 0 |
| 2. XLHED-unrelated infections | 5 (26) | 7 | 0 | 2 (33) | 4 | 0 |
| 3. Unexplained fevers | ||||||
| with seizure | 1 (5) | 2 | 2 | 0 (0) | 0 | 0 |
| without seizure | 1 (5) | 1 | 0 | 1 (17) | 1 | 0 |
| 4. Allergic reactions | 5 (26) | 8 | 2 | 1 (17) | 1 | 0 |
| 5. Developmental retardation | 5 (26) | 6 | 0 | 1 (17) | 2 | 0 |
| 6. Other | 6 (32) | 11 | 3 | 1 (17) | 5 | 2 |